Trial results for a study investigating stereotactic body radiotherapy (SBRT) in Pancreatic Cancer were posted on ClinicalTrials.gov on 2025-09-12. The study determined the maximum tolerated dose (MTD) of five-fraction SBRT to be 50 Gray.
Background
Pancreatic cancer remains one of the most challenging malignancies to treat, often diagnosed at advanced stages. Stereotactic body radiotherapy (SBRT) is a highly precise form of radiation therapy that delivers high doses of radiation to a tumor in a few treatment sessions, aiming to maximize tumor control while minimizing damage to surrounding healthy tissues. Determining the maximum tolerated dose (MTD) for such therapies is crucial for establishing safe and effective treatment protocols, especially in sensitive areas like the pancreas.
Trial design
This completed dose-escalation study enrolled 30 participants with Pancreatic Cancer. The primary objective was to determine the maximum tolerated dose (MTD) of five-fraction stereotactic body radiotherapy (SBRT) in this patient population. The trial aimed to identify a radiation dose that could be safely administered while evaluating its feasibility.
Key results
The study successfully identified the maximum tolerated dose for five-fraction stereotactic body radiotherapy. For all participants, the Maximum Tolerated Dose was determined to be 50 Gray.
What this means
The determination of a maximum tolerated dose of 50 Gray for five-fraction stereotactic body radiotherapy in pancreatic cancer provides a critical benchmark for future clinical research and treatment planning. This finding helps establish a safe upper limit for SBRT dosing in this context, which can inform the design of subsequent efficacy trials or guide clinical practice in dose selection. For patients with pancreatic cancer, this result contributes to the ongoing effort to optimize radiation therapy approaches, potentially leading to more effective and safer treatment regimens.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT02454140, titled "Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer", were posted on 2025-09-12 on clinicaltrials.gov.